中文
Tissue Regeneration Therapeutics (TRT) develops our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) technology platform, to provide licensing opportunities to collaborating partners.

Together we create cell and regenerative strategies that maximize the utility of publicly sourced tissue – for therapies that address important health care issues of today.

Together, we build very powerful biology.

NEWS!

July 10, 2013 - Tissue Regeneration Therapeutics Inc. (TRT) raises $3.25 Million to accelerate the development of its Mesenchymal Cell therapeutics platform
(click to read more)

Nov. 13, 2012 - TRT’s HUCPVCs Outperform Bone Marrow Cells in Repairing Damaged Hearts
(click to read more)